This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.

Petrioli, R., Coratti, A., Correale, P., D'Aniello, C., Grimaldi, L., Tanzini, G., et al. (2002). Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, 25(5), 468-473 [10.1097/00000421-200210000-00009].

Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.

D'ANIELLO, CARLO;GRIMALDI, LUCA;TANZINI, GABRIELLO;CIVITELLI, SERENELLA;MARZOCCA, GIUSEPPE;PIRTOLI, LUIGI;FRANCINI, GUIDO
2002-01-01

Abstract

This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) ( p= 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy ( p= 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.
Petrioli, R., Coratti, A., Correale, P., D'Aniello, C., Grimaldi, L., Tanzini, G., et al. (2002). Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, 25(5), 468-473 [10.1097/00000421-200210000-00009].
File in questo prodotto:
File Dimensione Formato  
adjuvant epirubicin with or without.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 220.95 kB
Formato Adobe PDF
220.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/44126
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo